18 - 70
liver, psc, primary sclerosing cholangitis
Phase 2 Drug Study
• 8 visits to the Gastroenterology and Hepatology Clinical Trial Unit during the Screening and Blinded Treatment parts of the study and 14 visits during the optional Open-Label Treatment part of the study
Take GS-9674 or placebo by mouth once daily
Imaging, blood draws, urine collection, and questionnaires at study visits
Males and females between 18-70 years of age with non-cirrhotic Primary Sclerosing Cholangitis (PSC)
Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.